A rat model for LGI1-related epilepsies. by Baulac, Stéphanie et al.
TitleA rat model for LGI1-related epilepsies.
Author(s)
Baulac, Stéphanie; Ishida, Saeko; Mashimo, Tomoji; Boillot,
Morgane; Fumoto, Naohiro; Kuwamura, Mitsuru; Ohno,
Yukihiro; Takizawa, Akiko; Aoto, Toshihiro; Ueda,
Masatsugu; Ikeda, Akio; LeGuern, Eric; Takahashi, Ryosuke;
Serikawa, Tadao
CitationHuman molecular genetics (2012), 21(16): 3546-3557
Issue Date2012-05-15
URL http://hdl.handle.net/2433/174159









































*Authors contributed equally to this study. 
1. Inserm U975, CRICM, Hôpital de la Pitié-Salpêtrière, Paris F-75013, France 
2. Université Pierre & Marie Curie-Paris 6, UMR_S975, Hôpital de la Pitié-Salpêtrière, Paris 
F-75013, France 
3. CNRS, UMR7225, Hôpital de la Pitié-Salpêtrière, Paris F-75013, France 
4. Institute of Laboratory Animals, Graduate School of Medicine, Kyoto University, Kyoto 
606-8501, Japan 
5. Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto 606-
8507, Japan 
6. Laboratory of Veterinary Pathology, Osaka Prefecture University, Izumisano, Osaka 598-
8531, Japan 
7. Laboratory of Pharmacology, Osaka University of Pharmaceutical Sciences, Takatsuki 
569-1094, Japan  
8. PhoenixBio Co. Ltd., Utsunomiya 321-0973, Japan 
9.  AP-HP, Département de Génétique et Cytogénétique, centre de génétique moléculaire et 
chromosomique, Hôpital de la Pitié-Salpêtrière, Paris F-75013, France 
# 
Correspondence should be addressed to: 
Tomoji Mashimo,  
Institute of Laboratory Animals, Graduate School of Medicine, Kyoto University, 
Yoshidakonoe-cho, Sakyo-ku, Kyoto 606-8501, Japan.  
E-mail: tmashimo@anim.med.kyoto-u.ac.jp 
Stéphanie Baulac, 
Institut du Cerveau et de la Moelle épinière (ICM)  
CRICM U975, Hôpital de la Pitié -Salpêtrière - 47, bd de l'hôpital, 75013 Paris, France   




Mutations of the leucine-rich glioma-inactivated 1 (LGI1) gene cause an autosomal-dominant 
partial epilepsy with auditory features also known as autosomal-dominant lateral temporal 
lobe epilepsy (ADLTE). Furthermore, LGI1 is the main antigen present in sera and 
cerebrospinal fluids of patients with limbic encephalitis and seizures, highlighting the 
importance of LGI1 in a spectrum of epileptic disorders. LGI1 codes for a neuronal secreted 
protein, which brain function is still largely unknown. Here, we generated Lgi1-mutant rats 
carrying a missense mutation (L385R) by ENU (N-ethyl-N-nitrosourea) mutagenesis. We 
found that the L385R mutation prevents secretion of Lgi1 protein by COS7 transfected cells. 
However, the L385R-Lgi1 protein was found at low levels in the brains and primary cultured 
neuron lysates of Lgi1-mutant rats, suggesting that mutant protein may be destabilized in vivo. 
Studies on the behavioral phenotype and intracranial electroencephalographic signals from 
homozygous and heterozygous Lgi1-mutant rats recalled several features of the human 
genetic disorder. We found that homozygous Lgi1-mutant rats generated early-onset 
spontaneous epileptic seizures from P10 and died prematurely. Adult heterozygous Lgi1-
mutant rats were much more susceptible to sound-induced, generalized tonic-clonic seizures, 
than control rats. Audiogenic seizures were suppressed by antiepileptic drugs such as 
carbamazepine, phenytoin and levetiracetam, that are commonly used to treat partial seizures, 
but not by the prototypic absence seizure drug, ethosuximide. Our findings provide the first 
rat model for a missense mutation in the Lgi1 gene, a model complementary to knockout mice 
in studies on Lgi1-related epilepsies, and reveal a new concept that LGI1 disease-causing 




Epilepsy, with a lifetime prevalence of 3%, is a frequent neurological disorder. Studies on 
familial idiopathic epilepsies have identified multiple disease-causing genes (1). For example, 
mutations in the leucine-rich glioma-inactivated 1 (LGI1) gene cause an inherited epilepsy 
syndrome designated either Autosomal Dominant Lateral Temporal Epilepsy (ADLTE) (2) or 
Autosomal Dominant Partial Epilepsy with Auditory Features (ADPEAF) (3). Focal seizures, 
with prominent auditory auras in about two thirds of patients, emerge in adolescence (4). 
Aphasic symptoms and other aberrant perceptions of a visual, vertiginous, epigastric, or 
psychogenic nature are also reported, and seizures can be triggered by noises or voices (5, 6). 
This seizure semiology tends to indicate a neocortical origin in the lateral temporal lobe. LGI1 
mutations (36 published to date (7)) have been found in up to 50% of ADLTE families and 
2% of sporadic cases (8). The role of LGI1 in neurological diseases was further expanded 
with the recent discovery that a subset of patients with limbic encephalitis (an autoimmune 
disorder associated with seizures in the majority of patients) (9, 10) has serum antibodies 
against LGI1. It is speculated that antibody-mediated disruption of LGI1 causes increased 
excitability, which results in seizures and other symptoms of limbic encephalopathy. 
In contrast to other genes linked to idiopathic epilepsies, LGI1 does not encode an ion 
channel subunit, but rather a secreted leucine-rich repeat (LRR) protein (11). To the exception 
of R407C (12), all tested LGI1 missense mutations tend to suppress protein secretion in in 
vitro overexpression systems (11, 13-17), indicating that extracellular levels of LGI1 may be 
critical to its pathophysiological effects. Lgi1 protein is expressed in the developing brain 
during embryogenesis and increases until adult, suggesting that Lgi1 may have a role during 
brain development (18-20). While its functions remain unclear, Lgi1 interacts with the 
presynaptic Kv1.1 voltage-gated potassium channel (21), ADAM22/ADAM23 (disintegrin 
and metalloproteinase domain 22 and 23)(22), ADAM11 (23) and NogoR1 (24). Insights into 
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the role of Lgi1 in epilepsy have emerged from recent studies on Lgi1 knockout in mice. 
There is a consensus that in homozygous Lgi1
-/-
 mice, the constitutive deletion of Lgi1 
induces early-onset spontaneous seizures with a premature death (19, 25, 26). Heterozygous 
Lgi1
+/ -
 mice do not generate seizures spontaneously, but they are more susceptible to seizure 
induction by pentylenetetrazole (25) and auditory stimuli (19).  Suppression of Lgi1 may be 
epileptogenic by modulating signaling in glutamatergic but not GABAergic synaptic 
transmissions (25, 26) as well as controlling postnatal maturation and pruning of 
glutamatergic synapses in the hippocampus (20) and retinogeniculate afferents in the thalamus 
(27).  
In the present study, we generated and characterized Lgi1-mutant rats carrying a missense 
mutation (L385R). We deciphered the mechanisms by which this mutation led to a loss of 
function in mammalian cells and primary neurons in culture. Electroencephalographic (EEG) 
monitoring was then used to define how the L385R-Lgi1 protein affected the phenotype of 
homozygous and heterozygous Lgi1-mutant rats in vivo. Finally, we examined actions of 
antiepileptic drugs on the audiogenic seizures in heterozygous Lgi1
+/L385R




Generation of Lgi1-mutant rats 
The ENU (N-ethyl-N-nitrosourea)-mutagenized F344/NSlc rat archive (KURMA: Kyoto 
University Rat Mutant Archive) was screened for mutations in the Lgi1 gene by a high-
throughput screening assay (28). A missense mutation (c.1154 T>G) in exon 8 of Lgi1 was 
found in one DNA sample of KURMA. This mutation resulted in the p.Leu385Arg/L385R 
amino acid substitution in the fourth epilepsy-associated-repeat (EAR) (Figure 1A), a residue 
highly conserved among vertebrates and invertebrates (Figure 1B). It was predicted to be “not 
tolerated” by the SIFT prediction tool of functional effects of variants 
(http://blocks.fhcrc.org/sift/SIFT.html). Interestingly, a well-documented ADLTE-causing 
mutation, p.Glu383Ala/E383A, was located close to the Rat mutation (3, 11, 13). The 
heterozygous Lgi1-mutant rat (Lgi1
+/L385R
) was recovered from the corresponding frozen 
sperm by intracytoplasmic sperm injection. Nine generations were backcrossed on the 
F344/NSIc inbred background to eliminate mutations potentially induced by ENU-
mutagenesis elsewhere in the genome (mean mutation frequency was ~1 in 4 x 10
6
 base pairs). 
Backcrossed Lgi1
+/L385R 
rats were then intercrossed to obtain wild-type (WT), heterozygous 
(+/L385R) and homozygous (L385R/L385R) animals. They were born in expected Mendelian 
ratios (+/+, n=17; homozygous, n=18; heterozygous, n=29; ² = 0.59, not significant) and sex 
ratios (Lgi1
L385R/L385R 
rats: 28 females, 36 males; ² = 1, not significant). 
L385R mutation impairs Lgi1 secretion in COS7 cells and cortical neurons 
We asked whether the rat L385R mutation impaired Lgi1 secretion, by transiently transfecting 
COS7 cells with Flag-Lgi1-L385R, Flag-Lgi1-E383A or Flag-Lgi1-WT (wild-type Lgi1). 
Using an antibody directed against amino acids 200-300 of Lgi1 (ab30868), Western blot 
analysis revealed the presence of wild-type Lgi1 and both mutants in the cell lysates. 
However, while wild-type Lgi1 protein was predominantly present in the cell culture medium, 
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we did not detect the Flag-Lgi1-L385R or the Flag-Lgi1-E383A mutants (Figure 2A). This 
shows that the L385R mutation prevents secretion of Lgi1 into the culture medium of COS7 
cells. 
We next examined endogenous Lgi1 secretion in isolated neurons of primary cortical 







blot analysis revealed only weak signal of 65 kDa in the neuron lysate of homozygous 
Lgi1
L385R/L385R
 rats, as well as in the neuron medium, indicating a low level of L385R-Lgi1 
protein in neurons (Figure 2B).  
L385R mutation affects in vivo stability of Lgi1 protein 
We then compared the endogenous L385R-Lgi1 protein level by Western blot in whole brain 




 and wild-type (Lgi1
+/+
) littermate rats. 
Immunoblot revealed a single band of 65 kDa in the lysate of Lgi1
+/+
. It was reduced by 
about half in Lgi1
+/L385R
 and was absent in Lgi1
L385R/L385R 
(n=5; Figure 3A). The low 
abundance of L385R-Lgi1 protein in brain was confirmed with a second antibody generated 
to the C-terminus of Lgi1 (sc-9583, Santa Cruz) in whole brain lysates from P9 rats (Figure 
1S, supplementary data). These findings were replicated in 3 additional litters of wild type, 
heterozygous and homozygous rats aged P5 and P9 (before onset of seizures) and P12 (after 
onset of seizures), indicating that shortened half-life of L385R-Lgi1 was not due to seizures-
induced damage (data not shown). We next analyzed synaptic fractions of hippocampal and 





rats, a strong signal was detected, indicating Lgi1 protein was present at the synapse. In 
contrast, similarly to whole brain homogenates, L385R-Lgi1 protein was not detected in the 
synaptic membrane fraction (Figure 3B), suggesting that it is probably unstable and thus not 
delivered to the synapse. 
We next asked whether low levels of L385R-Lgi1 protein resulted from a preferential 
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 (n=7) and Lgi1
+/+
 (n=5) littermate rats and analyzed Lgi1 
transcript expression by quantitative RT-PCR. Relative levels of the L385R-Lgi1 transcript 
were not significantly different from levels of the Lgi1
+/+
 transcript (Kruskal-Wallis test, P 
non significant; Figure 3C). These results suggest that low neuronal levels of L385R-Lgi1 
protein may result from a rapid turnover of the protein rather than the transcript. 
L385R mutation has no major effect on in vitro neuronal growth 
We asked whether this L385R mutation modified the growth of primary neurons plated on 
poly-L-lysine coated culture vessels. Cortical and hippocampal neurons from E19 rats were 
co-cultured for 3 weeks and examined daily. No differential effect on life span or neurite 




rats (Image J measurement of total 
neurite network length, Kruskal-Wallis test, P non significant) (Figure 4A). No major 
morphological differences were detected between hematoxylin-stained brains of P12 
Lgi1
L385R/L385R




 littermates (Figure 4B).  
Homozygous Lgi1-mutant rats are epileptic and die prematurely 
At birth, we detected no differences in appearance or behavior of homozygous Lgi1
L385R/L385R 




 littermates. During the second postnatal week, 
Lgi1
L385R/L385R
 pups began to exhibit spontaneous seizures (Figure 5A, movie 1). They 
occurred at a mean frequency of 8±2.8 per hour (mean± SD, n=8) from P10. Ictal epileptic 
discharges (n=11 electro-clinical seizures) were recorded by intracranial 
electroencephalography (EEG) in two homozygous Lgi1
L385R/L385R 
pups (Figure 5B). Seizures 
typically consisted of sequences of (i) hypertonic, often asymmetric, trunk, limb and tail 
postures, (ii) clonies of all limbs or jerking. EEG records began with rhythmic 5-7 Hz spike 
activity which increased in amplitude. It was replaced by polyspike-and-wave complexes at 1 
Hz during jerking episodes which slowed (0.5 Hz) as the seizure terminated. Seizures were 
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sometimes associated with motor automatisms, such as chewing. Such spontaneous epileptic 
activity was never observed in age-matched heterozygous Lgi1
+/L385R




As seizures emerged, Lgi1
L385R/L385R
 rat pups began to lose body weight. At P15, the body 
weight of Lgi1
L385R/L385R





 rats (Figure 6A), and development slowed dramatically (Figure 6B). All 
homozygous Lgi1
L385R/L385R
 rats died prematurely and the Kaplan-Meier curve revealed a 
mean lifetime of 13 days (n= 10). No homozygous Lgi1
L385R/L385R





littermates had died at this age (Figure 6C). Possibly, this early 
mortality results from a failure to feed due to seizures.  
Heterozygous Lgi1-mutant rats display increased audiogenic seizure vulnerability 
Heterozygous Lgi1
+/L385R 
rats appear normal, are fertile and live for at least one year. 
Spontaneous clinical seizures have never been observed either in pups or adults. Since partial 
seizures can be triggered by audiogenic events in ADLTE patients, we tested the 
susceptibility of heterozygous Lgi1-mutant rats to audiogenic seizures (AGS). A single 120 




rats at 3, 5, 8 or 
12 weeks of age, possibly due to this rat strain resistance. Acoustic priming (5 min, 10 kHz, 
120 dB) was thus applied to rat pups aged P16, corresponding to the critical period when rats 
become seizure-prone (29). Primed rats were then tested for audiogenic seizures at 8 weeks of 





(n=14) rats at 8 weeks (Table 1). Following wild running, 
we noted that auditory stimulation yielded generalized tonic-clonic seizures (GTCS) in all 
Lgi1
+/L385R 
rats, but only in 28 % of Lgi1
+/+
 rats (100 % versus 28 %, 2=36, P =1.9 10-9) 





 rats (Student’s t test, P=2.7 10-2; Figure 7B). The duration of wild 
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rats, probably since wild running was 
more rapidly replaced by a GTCS in Lgi1
+/L385R 
rats (Student’s t test, P=6.8 10-5; Figure 7C). 




rats (Student’s t 
test, P=4.5 10
-1
; Figure 7D).  





 rats (n=1) during auditory stimuli (Figure 8). During wild running, movement artifacts 
tended to obscure EEG signals. After running terminated, EEG signals were strongly 
suppressed in the tonic phase of Lgi1
+/L385R 
rats and the immobility phase of Lgi1
+/+
 rats. 
During the clonic seizure phase in Lgi1
+/L385R 
rats, continuous rhythmic slow activity at 2-3 Hz 
was detected in cortex and hippocampus. EEG signals were then suppressed, as Lgi1
+/L385R
 
rats remained immobile until auditory stimuli ceased.  
Effect of antiepileptic drugs on audiogenic seizures 





rats. We administered carbamazepine, phenytoin, levetiracetam 
and ethosuximide intraperitoneally (20 mg/kg) at 30 min before the auditory stimuli in 8 
week-old rats (Table 1, movie 3). Both wild running and GTCS were completely inhibited by 




 rats. Levetiracetam prevented wild 
running and GTCS in 3 of 4 Lgi1
+/L385R
 rats. No ictal EEG activity was detected during 
auditory stimulation (not shown). Ethosuximide, a prototypic generalized absence seizure 
drug, had no effect on seizures of Lgi1
+/L385R
 rats (n=4).  
DISCUSSION 
Here we present the first genetically-engineered animal model to express a missense mutation 
in the Lgi1 gene. We generated and characterized a Lgi1-mutant rat with a missense mutation 
(L385R) and studied its functional consequences in vivo. We first examined the impact of the 
mutation using in vitro overexpression paradigm. Our results showed that this mutation 
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prevented Lgi1 secretion in transiently transfected COS7 cells. This variant is thus deleterious 
and apparently shares common effects with ADLTE-causing missense mutations which 
nearly all decrease protein secretion, except one (30). Testing endogenous expression levels 
of the mutated Lgi1 protein in cultured cortical neurons of Lgi1-mutant animals revealed very 
low levels of L385R-Lgi1 protein, both in extracellular medium from cultures and also in 
neuron lysates. Moreover, endogenous levels of Lgi1 protein were also substantially lower in 
the brain of Lgi1-mutant animals than of wild-type littermates. Probably, in vivo, the L385R 
mutation favors misfolding and so reduces Lgi1 protein stability, causing its degradation 
through protein quality control mechanisms. This is consistent with in silico computational 
models predicting that a number of disease-causing mutations alter protein folding (30). Thus 
a physiopathological loss-of-function may emerge not only due to a failure of protein 
secretion but also from a lack of correctly folded neuronal Lgi1. This new mechanism must 
be considered together with previous suggestions of a defective secreted extracellular Lgi1 
(acting as a ligand for ADAM22/23 at the post-synaptic) (22), rather than cytoplasmic 
(through the modulation of Kv1.1 channel) (21). Here, the Lgi1-mutant rat carrying a 
missense mutation located nearby a well-characterized naturally occurring missense mutation 
found in ADLTE patients (3, 11, 13), lacks both cytoplasmic and extracellular Lgi1. While 
cortical tissue from patients is not available, we speculate that ADLTE-associated missense 
mutations might also lead to instability in vivo, causing a haploinsufficiency. We note such a 
deficiency in Lgi1 occurs in patients with limbic encephalitis and seizures, in which immune-
mediated disruption of LGI1 results in hyperexcitability (31).  
 While focal epilepsies are often associated with brain lesions, we detected no major 
abnormality in brain morphology of Lgi1-mutant rats. Since Lgi1 may promote neurite 
outgrowth in vitro via ADAM23 (32) and NogoR1 (24), we examined neuron growth in co-
cultures of cortical and hippocampal neurons from Lgi1-mutant rats. We detected no obvious 
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defect in neuritic outgrowth or neuronal life-span suggesting that neuronal network activity, 
rather than dendritic architecture may contribute to hyperexcitability in this rat. 
The phenotype of mutant rats possessed similarities to the ADLTE syndrome. Epileptic 
seizures, associated with cortical and hippocampal ictal epileptiform activity, emerged at P10 
in homozygous Lgi1
L385R/L385R 
pups. Frequent and severe seizures led to death of the 
homozygous animals around P13. Lgi1
+/L385R 
rats, which carry a heterozygous missense 
mutation similar to ADLTE patients, did not generate seizures spontaneously but were highly 
susceptible to audiogenic seizures, as patients with LGI1 mutations are susceptible to 
auditory-induced seizures (seizures may be triggered by noises or voices) (6). In addition, we 
showed that rat audiogenic seizures responded to the same drugs as used in the human: they 
were suppressed by two antiepileptic drugs, carbamazepine and phenytoin, that target voltage-
gated channels, but also by levetiracetam which anticonvulsant activity is mediated via 
interaction with the synaptic vesicle protein 2A (SV2A)(33, 34). Since Lgi1 co-
immunoprecipitates with several other neuronal vesicle-related proteins (35), this latter 
pathway involving SV2A might be promising for preventing seizures in this syndrome. As 
expected, ethosuximide, a first choice drug for absence seizures, did not prevent audiogenic 
seizures. This rat model thus permitted more detailed studies on audiogenic seizures and tests 
on anti-epileptic molecules. As SV2A, Lgi1 may point towards novel antiepileptic therapies 
for drug-resistant patients. 
The Lgi1-mutant rat is therefore a relevant animal model for modeling Lgi1-related 
epilepsy. It shares several features with the phenotype of Lgi1 knockout mice (19): (i) a 
natural history of severe early onset spontaneous seizures (age at onset, semiology of seizures, 
EEG pattern and premature death associated with loss of body weight), (ii) an absence of 
morphological abnormalities, (iii) audiogenic seizures in heterozygous rats recapitulating the 
genetic cause and mimicking the auditory triggering of seizure in the human. We note the 
similar age of seizure onset (around P10) in Lgi1-null mice and Lgi1-mutant rats that might be 
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consistent with the timing of Lgi1 expression and maturation of glutamatergic synapses 
similar to both species. We were initially surprised to define a similar phenotype in 
homozygous Lgi1-mutant rats (L385R-Lgi1) and Lgi1-null mice (absence of Lgi1). However, 
our discovery of a rapid degradation of Lgi1-L385R suggests the point mutation induces a 
haploinsufficiency that is equivalent to a gene knockout. 
In conclusion, we report a unique and original rat model of Lgi1-related epilepsies, which 
is complementary to knockout mice. It gave us the opportunity to better understand the 
consequences of missense mutations on the fate of the mutant protein, revealing a major 
finding that L385R-Lgi1 protein is unstable in vivo. Thanks to this model, we also 
investigated the consequences of Lgi1 deficiency on the neuronal and neurite outgrowth. 
Finally, the heterozygous Lgi1
+/L385R 
rats allowed us to initiate pharmacological studies on 
their auditory triggered-seizures which are close to those occurring in ADLTE patients. 
MATERIAL AND METHODS 
ENU mutagenesis in rats 
ENU mutagenesis and screening protocols using MuT-POWER in rats have been described 
(28). The sperm archive KURMA has been deposited in the National BioResource Project-Rat 
in Japan (NBRP-Rat: www.anim.med.kyoto-u.ac.jp/nbr). Primers were designed to amplify 
by PCR the exonic region of the rat Lgi1 gene from ~50 bp flanking each intron 
(supplemental Table 1). Sequencing was performed with BigDye terminator mix, followed by 
the protocol for the Applied Biosystems 3100 DNA Sequencer. Lgi1-mutant rats were 
recovered from frozen sperm by intracytoplasmic sperm injection. 
Animals 
Lgi1-mutant rats (strain name, F344-Lgi1
m1kyo
) were deposited in NBRP-Rat (N° 0656). They 
were kept and bred at the Institute of Laboratory of Animals, Graduate School of Medicine, 
Kyoto University in air-conditioned rooms under a 14h light/10h dark cycle. Animal care and 
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experiments conformed to the Guidelines for Animal Experiments and were approved by the 
Animal Research Committee of Kyoto University. 
Genotyping of Lgi1-mutant rats 
Exon 8 of Lgi1 was amplified by PCR with Ex8-1 primers (supplemental Table 1) using the 
Ampdirect Plus
®
 PCR buffer (Shimadzu) and FTA
®
 card for blood samples. PCR products 
were then sequenced with BigDye terminators mix.  
Western blots 
Littermate rat pups aged postnatal day 9 (P9) and P12 were decapitated; whole brains were 
quickly removed and lysed in 3M urea, 2.5% SDS, 50 mM Tris, 30 mM NaCl buffer (total 
brain homogenates). For synaptic fractions, brains of littermate rats were homogenized in 50 
mM Tris, 5 mM EDTA, 120 mM NaCl with complete inhibitor cocktail, spun for 1h at 
165,000 × g and pellets resuspended with 1% Triton X-100. Total protein concentrations were 
determined by the BCA method (Pierce). Twenty-five g of each sample were separated on 
10 % Tris-glycine polyacrylamide gels were analyzed by Western blot with the following 
antibodies: rabbit polyclonal anti-Lgi1 antibody (ab30868; 1ug/ml; Abcam), goat polyclonal 
anti-Lgi1 antibody (sc-9583; 1ug/ml; Santa Cruz) and rabbit anti-actin antibody (1/1000, 
Sigma Aldrich), and detected with the SuperSignal Chemiluminescent Substrate (Pierce).  
Cell culture and transfection  
Drs. K. Senechal and J. Noebels kindly provided the mouse wild-type Lgi1 cDNA with a Flag 
tag at the N-terminus. Lgi1-E383A and Lgi1-L385R were generated using the QuikChange® 
Site-Directed Mutagenesis Kit. COS7 cells were cultured in DMEM containing 10% fetal 
bovine serum, penicillin and streptomycin. Transient transfections were performed using 
Lipofectamine
TM
 2000 according to instructions (Invitrogen), followed by a 14-16 hour 
incubation in serum-free media. Cells and media were analyzed 24-36 hours after transfection. 
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Cell lysates and conditioned media were prepared as described (13) and analyzed by Western 
blot.  
Neuronal cultures 
Cortex and hippocampus were removed from ten rat embryos aged embryonic day 19 (E19) 
and dissociated using the Nerve-Cell culture system (Sumitomo Bakelite co). Neurons were 
plated at 10
5
 cells/ml in neuron culture medium (Sumitomo Bakelite co) on 35mm poly-L-
Lysine coated dishes. They were cultured for 12 days and then lysed as previously described 
in COS7 cells. Neuronal outgrowth was imaged and measured automatically using ImageJ. 
Quantitative reverse transcription PCR 
Whole brains were removed from P9 rats (n=6) and stored in RNAlater® solution (Applied 
Biosystems). Total RNA was isolated with RNeasy Miniprep columns (Qiagen) and 
contaminating DNA was depleted using RNase-free DNase. First-strand cDNA was 
synthesized from 5 µg of total RNA by oligo dT-primed reverse transcription 
(ThermoScript™ Reverse Transcriptase, Invitrogen). Quantitative PCR were performed as 
triplicates using the QuantiFast Multiplex PCR Kit (Qiagen) using predesigned probes for 
Lgi1 (QuantiFast Probe Assays) and peptidyl prolyl isomerase A (PPIA) as a reference gene 





 littermates (n=1), Lgi1
+/L385R
 (n=2) and Lgi1
L385R/L385R 
(n=1) aged P12 were deeply 
anesthetized with sodium pentobarbital (50 mg/kg by intraperitoneal injection). Brains were 
removed, fixed in Bouin's fixative and embedded in paraffin. Morphological changes were 
evaluated from hematoxylin and eosin stained, 4 µm thick paraffin sections.   
Animal surgery and intracranial EEG recordings 
Cortical EEG was recorded from homozygous P10 rats (during 3 continuous hours) and 
heterozygous rats aged 8 weeks. Rats were anesthetized with an intraperitoneal injection of 
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sodium pentobarbital (40 mg/kg) and the heads were fixed in a stereotaxic instrument. One-
mm-diameter screw electrodes were implanted into the epidural space of the left frontal cortex. 
A reference electrode was fixed on the frontal cranium. For hippocampal EEG, 0.2-mm-
diameter stainless-steel electrodes were implanted in the hippocampus (3.8 mm caudal, 2.0 
mm lateral to the bregma and 2.2 mm from the cortex surface). A miniature plug was 
positioned and fixed on the midline of the skull to provide electrical connections. After 1-hour 
recovery period for P10 rats and 1-week recovery period for 8-week old rats, animals were 
placed in a shielded box (40×40×40 cm
3
) and the EEG signals were amplified with a 
sampling rate of 0.5–100 Hz with a 8-channel system (MEG-6108; Nihon Kohden) and 
recorded (RTA-1100; Nihon Kohden) under free-moving conditions. The signals were stored 
in a computer for analysis (ML845; PowerLab). Behavioral changes were simultaneously 
observed with video recording.  
Acoustic stimulation 
The testing apparatus consisted of a 17×25×13 cm plastic cage placed inside a larger sound-
proof box. Acoustic stimulation was administered from a loudspeaker (JBL Professional) 
centrally placed on the cover of the cage. Tone bursts were delivered by a sound stimulator 





littermate rats were exposed individually to intense 
auditory stimulation after 1-minute habituation. Priming stimulation was performed in P16 
rats with a sound stimulus of 120 dB at 10 kHz for 5 min. Target stimulation consisted of a 
120 dB sound stimulus at 10 kHz for 1 min at 8 weeks (36). The onset, latency, and duration 
of wild running and GTCS were measured from video records. 
Antiepileptic drugs administration 
Antiepileptic drugs (Sigma-Aldrich) were administrated intraperitoneally 30 minutes before 
target stimulation with therapeutic range (20 mg/Kg). Carbamazepine and Ethosuximide were 
first dissolved in polyethylene glycol 400 then in water. Phenytoin was first dissolved in 0.5 N 
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NaOH and then diluted with saline solution. Levetiracetam was dissolved in saline solution. 
FIGURE LEGENDS 
Figure 1. The L385R mutation. (A) Schematic representation of the Lgi1 protein showing 
its domain organization and location of the L385R mutation. The protein is composed of 2 
structural domains: four N-terminal leucine-rich repeats (LRR in blue) and seven epilepsy-
associated repeats (EAR in yellow) in the C-terminal half of the protein. (B) Multiple protein 
alignments of Lgi1 protein showing strong conservation of L385 residue in both vertebrates 
and invertebrates using the Alamut® Mutation Interpretation Software. 
Figure 2. Lack of secretion of L385R-Lgi1 mutant protein in COS7 cells and cortical 
neurons. (A) COS7 cells were transiently transfected with the wild-type (WT) or indicated 
mutant Flag-Lgi1-expressing plasmids. Cell lysates and cell media were analyzed by Western 
blot with anti-Lgi1 antibody (ab30868). Lgi1-WT was detected in both the lysate and the 
culture media, while Lgi1-L385R and Lgi1-E383A mutants were only detected in the cell 







 littermate rats were cultured. Cell lysates and media were 
analyzed by Western blot with anti-Lgi1 antibody (ab30868). L385R-Lgi1 mutant protein was 
weakly detected in both the lysates and the culture media, in contrast to the wild-type Lgi1 
protein. Ponceau staining indicated equal loading in each well. 
Figure 3. Instability of the L385R-Lgi1 mutant protein. (A) We assessed Lgi1 protein 




 (n=1) and 
Lgi1
L385R/L385R 
(n=5) littermate rats aged postnatal day 12 (P12). Wild-type Lgi1 protein was 
detected, but not L385R-Lgi1. Equal amounts of proteins were loaded as shown by the actin 







(n=1) littermate rats aged P12 were loaded. L385R-Lgi1 mutant protein was not 
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(n=6) rat brains. Data are means +/- SDs of triplicates (P non significant) 
corresponding to expression of Lgi1 transcript in relation to the housekeeping gene PPIA. 
Figure 4. No major effect of L385R mutation on neuronal growth. (A) Photography of 
cortical neurons from E19 Lgi1
+/+
 (n=2) and Lgi1
L385R/L385R 
(n=6) littermate rats after 4 or 7 
days in culture. We observed no major difference on the length of neurites or survival in 
Lgi1
L385R/L385R 
rats compared to Lgi1
+/+
 littermates. Background was subtracted using ImageJ. 





 (n=1) and Lgi1
L385R/L385R 
(n=1) littermates aged P12. 
Figure 5. Spontaneous epileptic seizures in homozygous Lgi1
L385R/L385R 
rats. (A) 
Photography during a spontaneous seizure in a P10 Lgi1
L385R/L385R
 rat showing asymmetric 
clonie of the four limbs. (B) Epidural EEG recording in a P10 Lgi1
L385R/L385R
 rat showing the 
onset and end of an electroclinical seizure (trace corresponds to left cortex). Behavioral 
modifications are correlated with EEG event; (i) Tonic attack, (ii) Jerking.  
Figure 6. Premature death and reduced body weight in homozygous Lgi1
L385R/L385R 
rats. 




 (n=7) and Lgi1
L385R/L385R
 (n=5) 
animals at birth. The body weight of Lgi1
L385R/L385R 





 rats after P10. (B) Photography shows Lgi1
L385R/L385R












 (n=10) rats from P0 to P17. All Lgi1
L385R/L385R
 rats had 
died at P17.  
Figure 7. Susceptibility to audiogenic seizures. (A) Primed rats were tested at 8 weeks for 
audiogenic seizures with a stimulus of 10 kHz, 120 dB applied for 1 min. Generalized tonic-
clonic seizures (GTCS) were induced in all Lgi1
+/L385R





(B) The time to onset of wild running was shorter in Lgi1
+/L385R 
rats than in Lgi1
+/+
 rats. (C) 




 rats. (D) The duration 





denotes P <0.01 and * denotes P <0.05 by student’s t-test.  
Figure 8. EEG recording in Lgi1
+/L385R 
rat during audiogenic seizure. Traces of typical 
cortical and hippocampal EEG responses to auditory stimuli from an 8-week-old Lgi1
+/L385R 
rat. Behavioral changes were correlated with EEG events; 1: Wild running, 2: Tonic attack, 3: 
Clonic convulsions, 4: Immobility, 5: Alternative knee bending exercise. Movement artefacts 
are present on the EEG signal during the wild running phase and mostly suppressed in the 
second tonic phase. Rhythmic low-voltage slow activities were observed in the third clonic 
phase, in cortex and hippocampus. They decreased in the fourth immobility phase, and were 
suppressed in the final phase until the end of the stimulus. Cx, cortex; Hp, hippocampus.  
MOVIE LEGENDS 
Movie 1. Video recording of a postnatal day 12 Lgi1
L385R/L385R
 pup during a spontaneous 
epileptic seizure. 
Movie 2. Video recording of a Lgi1
+/L385R
 rat aged 8-weeks during an audiogenic seizure. 
Movie 3. Video recording during auditory stimulus of a Lgi1
+/L385R
 rat aged 8-weeks injected 
with carbamazepine. 
SUPPLEMENTARY FIGURE LEGENDS 
Figure 1S. Endogenous Lgi1 expression. We assessed Lgi1 protein expression by Western 






 littermate rats 
aged P9. Wild-type Lgi1 protein was detected, but not L385R-Lgi1 using the sc-9583 
antibody against the C-terminus of Lgi1 (A) and the ab30868 antibody directed against amino 
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acid 200-300 (B). Asterisk indicates non-specific band. Equal amounts of proteins were 
loaded as shown by the actin control. 
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 +/+  -  +  - 11 11 0 0 
 +/+  +  +  - 14 0 10 4 
 +/ L385R  -  +  - 15 15 0 0 
 +/ L385R  +  +  - 22 0 0 22 
 +/+  +  + Carbamazepine 3 3 0 0 
 +/+  +  + Phenytoin 2 2 0 0 
 +/ L385R  +  + Carbamazepine 6 6 0 0 
 +/ L385R  +  + Phenytoin 4 4 0 0 
 +/ L385R  +  + Levetiracetam 4 3 1 0 
 +/ L385R  +  + Ethosuximide 4 0 0 4 
 +/ L385R  +  + Saline solution 5 0 0 5 
 
Table 1: Audiogenic seizures. Prime stimulation at age P16 was applied as follow: 120 dB, 10 kHz for 5min. Target stimulation at 8-weeks of 





Lgi1 exons  Forward Primer Reverse Primer  Amplicon size (bp) 
Exon1 gctcccatctcagcacctc tccaccagctggaattcttt 552 
Exon2 cggattaacgtaagctctgt tccaaatacatgccatatca 272 
Exon3 tgagcgtgtaactgttctca aacaacatcctcatttggtc 275 
Exon4 ctgtctgaccaaatgaggat tcaattaacccaaatcaacc 275 
Exon5 ttgaattttcactacatttttgt agccagtgatttcttaggtc 272 
Exon6 tactgcaaatgcagcagac tgctgtagaaatggttttca 370 
Exon7 catcttcttttcctatttttgc ccctctgtcaaagcagttta 366 
Exon8-1 ccacacatctaatgtctcatctgtt aggatcaaatgaggtgttctgag 495 
Exon8-2 tgatgtggaatacctagaaatagcc gaaaattacgcttgttaatggacac 508 
Exon8-3 aagtttcaggagttaaatgttcagg aacatgtttataaattatgggaaatca 687 
 
 































Flag-Lgi1  64 kDa  
COS7 lysates COS7 media A 
Neuron lysates Neuron Media 
Lgi1 
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Postnatal age (days) 
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Supplementary figure 1 
